Table 2.

Bevacizumab, Carboplatin, and Paclitaxel Versus Carboplatin Versus Carboplatin Plus Paclitaxel (control; Fig 3)

Measure	Score/Result
Clinical benefit score (maximum, 180 points)
Improvement ([12.3 − 10.3]/10.3 = 19%)
OS score (1 × 16)	16
Toxicity score (maximum, 20 points)
Carboplatin plus paclitaxel (control)	15 (grade 3 to 5)
Bevacizumab, carboplatin, and paclitaxel	22 (grade 3 to 5)
Toxicity score ([22 − 15]/15 = 46%)	0
Bonus points (maximum, 30 points)
Palliation	0
Treatment-free interval	0
Total bonus points	0
Net health benefit (maximum, 130 points)	16
Drug cost (monthly)
Drug acquisition cost	$11,907.87
Patient copay	Calculated per patient

Abbreviation: OS, overall survival.